Zoloft Indications/Uses

Sertraline hydrochloride (Zoloft) is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. Following satisfactory response, continuation with Sertraline hydrochloride (Zoloft) therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.
Sertraline hydrochloride (Zoloft) is indicated for the treatment of obsessive-compulsive disorder (OCD). Following satisfactory response, continuation with Sertraline hydrochloride (Zoloft) therapy is effective in preventing relapse of the initial episode of OCD.
Sertraline hydrochloride (Zoloft) is indicated for the treatment of pediatric patients 6 years of age and older with OCD.
Sertraline hydrochloride (Zoloft) is indicated for the treatment of panic disorder, with or without agoraphobia. Following satisfactory response, continuation with Sertraline hydrochloride (Zoloft) therapy is effective in preventing relapse of the initial episode of panic disorder.
Sertraline hydrochloride (Zoloft) is indicated for the treatment of post-traumatic stress disorder (PTSD). Following satisfactory response, continuation with Sertraline hydrochloride (Zoloft) therapy is effective in preventing relapse of the initial episode of PTSD.
Sertraline hydrochloride (Zoloft) is indicated for the treatment of social phobia (social anxiety disorder). Following satisfactory response, continuation with Sertraline hydrochloride (Zoloft) therapy is effective in preventing relapse of the initial episode of social phobia.
Pre-menstrual Dysphoric Disorder (PMDD) - Sertraline hydrochloride (Zoloft) is indicated for the treatment of pre-menstrual dysphoric disorder (PMDD).
The efficacy of Sertraline hydrochloride (Zoloft) in the treatment of PMDD was established in two placebo-controlled trials of female outpatients treated for 3 menstrual cycles who met criteria for the DSM-III R/IV category of PMDD (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationship with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant.
The effectiveness of Sertraline hydrochloride (Zoloft) in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Sertraline hydrochloride (Zoloft) for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Dosage & Administration).